Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADXS
  • CUSIP:
Key Metrics:
  • Previous Close: $9.16
  • 50 Day Moving Average: $8.69
  • 200 Day Moving Average: $9.91
  • 52-Week Range: $5.23 - $16.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.80
  • P/E Growth: 0.00
  • Market Cap: $360.92M
  • Outstanding Shares: 40,147,000
  • Beta: 2.13
Profitability:
  • Return on Equity: -72.97%
  • Return on Assets: -61.65%
Debt:
  • Current Ratio: 5.77%
  • Quick Ratio: 5.77%
Additional Links:
Companies Related to Advaxis:

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.00 (166.67% upside)

Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017HC WainwrightSet Price TargetBuy$23.00View Rating Details
11/29/2016Cantor FitzgeraldInitiated CoverageBuy$19.00View Rating Details
9/9/2016Jefferies Group LLCReiterated RatingBuy$24.00View Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00View Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00View Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00View Rating Details
9/11/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details
6/26/2015MLV & Co.Initiated CoverageBuyView Rating Details
3/17/2015Noble FinancialReiterated RatingBuyView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/13/2016        
4/16/2015($0.31)($0.33)ViewN/AView Earnings Details
9/23/2014($0.25)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
Current Year EPS Consensus Estimate: $-2.17 EPS
Next Year EPS Consensus Estimate: $-2.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.61)($0.61)($0.61)
Q3 20161$0.55$0.55$0.55
Q4 20161($0.58)($0.58)($0.58)
Q1 20171($0.51)($0.51)($0.51)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.59)($0.59)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Advaxis (NASDAQ:ADXS)
Insider Ownership Percentage: 4.56%
Institutional Ownership Percentage: 57.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.28View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Advaxis (NASDAQ:ADXS)
DateHeadline
News IconConsensus Buy Rated Stocks: Advaxis, Inc. (NASDAQ:ADXS ... - Davidson Register (NASDAQ:ADXS)
davidsonregister.com - February 21 at 5:58 AM
News IconWhere is Advaxis, Inc. (NASDAQ:ADXS) Headed Near Term? - Rockville Register (NASDAQ:ADXS)
rockvilleregister.com - February 21 at 5:58 AM
News IconEye on Technicals Advaxis Inc. (ADXS) - Benton Bulletin (NASDAQ:ADXS)
bentonbulletin.com - February 18 at 3:19 PM
News IconEarnings at a Glance For Advaxis, Inc. (NASDAQ:ADXS): What Are Analysts Predicting For the Stock? - Winfield Review (NASDAQ:ADXS)
winfieldreview.com - February 18 at 3:19 PM
News IconStock Levels in View for Advaxis, Inc. (NASDAQ:ADXS) - Piedmont Register (NASDAQ:ADXS)
piedmontregister.com - February 17 at 6:45 PM
News IconActive Trading Watch on Shares of Advaxis Inc. (ADXS) - BVN (NASDAQ:ADXS)
bvnewsjournal.com - February 17 at 6:45 PM
News IconEarnings Wrap Up & Price Target Focus on Advaxis, Inc. (NASDAQ:ADXS) - Winfield Review (NASDAQ:ADXS)
winfieldreview.com - February 16 at 3:22 PM
News IconPeeling Back The Layers on Advaxis, Inc. (NASDAQ:ADXS): Analysts & Street Weigh In - Winfield Review (NASDAQ:ADXS)
winfieldreview.com - February 14 at 8:36 PM
News IconTechnical Levels in Focus: Advaxis Inc. (ADXS) - BVN (NASDAQ:ADXS)
bvnewsjournal.com - February 14 at 8:36 PM
News IconPrice Target & Session Watch on Advaxis, Inc. (NASDAQ:ADXS) - Rockville Register (NASDAQ:ADXS)
rockvilleregister.com - February 14 at 1:35 AM
News IconBustling Stock in Focus: Advaxis, Inc. (NASDAQ:ADXS) - Aiken Advocate (NASDAQ:ADXS)
aikenadvocate.com - February 13 at 3:32 PM
News IconStocks in Analyst Viewfinder: Advaxis, Inc. (NASDAQ:ADXS) - Rockville Register (NASDAQ:ADXS)
rockvilleregister.com - February 13 at 3:32 PM
News IconEPS Of Advaxis, Inc. (NASDAQ:ADXS) At $-0.51 - Stock Observer (NASDAQ:ADXS)
www.thestockobserver.com - February 13 at 3:32 PM
News IconTrading Focus: Eye on Shares of Advaxis Inc. (ADXS) - Baldwin Journal (NASDAQ:ADXS)
baldwinjournal.com - February 13 at 3:32 PM
News IconStock Scanner: Watching the Numbers on Advaxis Inc. (ADXS) - Sherwood Daily (NASDAQ:ADXS)
sherwooddaily.com - February 10 at 8:43 PM
News IconMarket Focus: Checking Up on Shares of Advaxis, Inc. (NASDAQ:ADXS) - Benton Bulletin (NASDAQ:ADXS)
bentonbulletin.com - February 10 at 8:43 PM
News IconSizling Stock Update: Advaxis, Inc. (NASDAQ:ADXS) - HugoPress (NASDAQ:ADXS)
hugopress.com - February 8 at 3:25 PM
News IconTrading Indicator Check on Advaxis Inc. (ADXS) - Providence Standard (NASDAQ:ADXS)
providencestandard.com - February 8 at 3:25 PM
News IconAdvaxis Inc (NASDAQ:ADXS) Announces First Patient in Phase 3 AIM2CERV Trial - Small Cap Exclusive (press release) (NASDAQ:ADXS)
smallcapexclusive.com - February 7 at 3:29 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Quarterly EPS Projection At $-0.51 - Stock Observer (NASDAQ:ADXS)
www.thestockobserver.com - February 6 at 3:24 PM
streetinsider.com logoAdvaxis (ADXS) Doses First Patient in Phase 3 AIM2CERV Trial - StreetInsider.com (NASDAQ:ADXS)
www.streetinsider.com - February 6 at 3:24 PM
finance.yahoo.com logoAdvaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer (NASDAQ:ADXS)
finance.yahoo.com - February 6 at 3:24 PM
News IconEarnings Snapshot & Analysts Target Update on Advaxis, Inc. (NASDAQ:ADXS)? - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 31 at 8:30 PM
us.rd.yahoo.com logoGOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer (NASDAQ:ADXS)
us.rd.yahoo.com - January 31 at 1:34 AM
us.rd.yahoo.com logo8:32 am Advaxis announces a study in metastatic cervical cancer selected for late-breaking data presentation at the Society of Gynecologic Oncology's annual meeting on women's cancer on March 12-15 (NASDAQ:ADXS)
us.rd.yahoo.com - January 31 at 1:34 AM
News IconChecking the Levels on Shares of Advaxis, Inc. (NASDAQ:ADXS) - The Tribune (NASDAQ:ADXS)
lakecitytribune.com - January 30 at 3:32 PM
News IconAre Analysts Predicting a Near-Term Upswing For Advaxis, Inc. (NASDAQ:ADXS)? - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 30 at 3:32 PM
News IconVolatility Watch on Shares of Advaxis, Inc. (NASDAQ:ADXS) - Gilbert Daily (NASDAQ:ADXS)
gilbertdaily.com - January 30 at 1:21 AM
News IconNews Impact Score Of Advaxis, Inc. (NASDAQ:ADXS) At 94 - Stock Observer (NASDAQ:ADXS)
www.thestockobserver.com - January 29 at 1:22 AM
News IconChart Indicators in Focus for Advaxis Inc. (ADXS) - Rives Journal (NASDAQ:ADXS)
rivesjournal.com - January 28 at 3:20 PM
News IconIs There Inherent Value in Advaxis, Inc. (NASDAQ:ADXS)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 27 at 9:44 PM
News IconFCF Score Check on Shares of Advaxis, Inc. (NASDAQ:ADXS) - The Tribune (NASDAQ:ADXS)
lakecitytribune.com - January 27 at 3:44 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Advaxis, Inc. (NASDAQ:ADXS) - Aiken Advocate (NASDAQ:ADXS)
aikenadvocate.com - January 26 at 8:38 PM
capitalcube.com logoAdvaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 26, 2017 (NASDAQ:ADXS)
www.capitalcube.com - January 26 at 3:34 PM
News IconEarnings in Full Force, Analysts Take Aim at Advaxis, Inc. (NASDAQ:ADXS) - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 25 at 3:25 PM
finance.yahoo.com logoNew Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported (NASDAQ:ADXS)
finance.yahoo.com - January 25 at 3:25 PM
News IconVolatile Stock Watch on Shares of Advaxis, Inc. (NASDAQ:ADXS) - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 25 at 2:20 AM
News IconPeeling Back The Layers on Advaxis, Inc. (NASDAQ:ADXS): Sell-Side Weighs In - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 24 at 8:42 PM
News IconAdvaxis, Inc. (ADXS) Under Analyst Spotlight - UK Market News - UK Market News (NASDAQ:ADXS)
www.ukmarketnews.co.uk - January 24 at 3:41 PM
realistinvestor.com logoEPS Projection Of Advaxis, Inc. (NASDAQ:ADXS) At $-0.495 - RealistInvestor.com (NASDAQ:ADXS)
www.realistinvestor.com - January 24 at 3:41 PM
News IconAnalysts Pounding The Pavement on Advaxis, Inc. (NASDAQ:ADXS): Consensus Update - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 24 at 3:41 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Advaxis, Inc. (NASDAQ:ADXS) - Prospect Journal (NASDAQ:ADXS)
prospectjournal.com - January 24 at 1:36 AM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Quarterly EPS Projection At $-0.56 - Stock Observer (NASDAQ:ADXS)
www.thestockobserver.com - January 23 at 3:22 PM
News IconTrading Scope: Following Levels on Shares of Advaxis Inc. (ADXS) - Sherwood Daily (NASDAQ:ADXS)
sherwooddaily.com - January 22 at 3:20 PM
News IconNews Impact Score Of Advaxis, Inc. (NASDAQ:ADXS) Set At 100 - Stock Observer (NASDAQ:ADXS)
www.thestockobserver.com - January 21 at 3:19 PM
News IconMarket Review: Indicator Watch for Advaxis Inc. (ADXS) - Rives Journal (NASDAQ:ADXS)
rivesjournal.com - January 20 at 8:25 PM
News IconAnalysts Pull Back the Curtain on Advaxis, Inc. (NASDAQ:ADXS): Consensus Update - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 20 at 8:25 PM
News IconAmplified Volatility Spotted in Shares of Advaxis, Inc. (NASDAQ:ADXS) - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 20 at 1:43 AM
News IconTrading Scope: Indicator Review for Advaxis Inc. (ADXS) - Sherwood Daily (NASDAQ:ADXS)
sherwooddaily.com - January 19 at 8:37 PM
News IconDevling Into Shares of Advaxis, Inc. (NASDAQ:ADXS), What Are Analysts Predicting for 2017? - Wall Street Beacon (NASDAQ:ADXS)
wsbeacon.com - January 19 at 8:37 PM

Social

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2017?

5 analysts have issued 1 year price objectives for Advaxis' shares. Their forecasts range from $19.00 to $34.00. On average, they anticipate Advaxis' share price to reach $24.00 in the next twelve months.

When will Advaxis announce their earnings?

Advaxis is scheduled to release their next quarterly earnings announcement on Wednesday, April, 13th 2016.

Who owns Advaxis stock?

Advaxis' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (10.22%), Broadfin Capital LLC (3.78%), Marshall Wace LLP (1.69%), State Street Corp (1.55%), Sarissa Capital Management LP (1.25%) and Allianz Asset Management AG (0.37%). Company insiders that own Advaxis stock include Adage Capital Partners Gp Llc, Daniel O'connor, David J Mauro, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn.

Who sold Advaxis stock? Who is selling Advaxis stock?

Advaxis' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, FMR LLC and Allianz Asset Management AG. Company insiders that have sold Advaxis stock in the last year include Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn.

Who bought Advaxis stock? Who is buying Advaxis stock?

Advaxis' stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Marshall Wace LLP, State Street Corp and A.R.T. Advisors LLC. Company insiders that have bought Advaxis stock in the last two years include Adage Capital Partners Gp Llc and Richard J Berman.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Advaxis stock cost?

One share of Advaxis stock can currently be purchased for approximately $9.00.

Advaxis (NASDAQ:ADXS) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Earnings History Chart

Earnings by Quarter for Advaxis (NASDAQ:ADXS)

Dividend History Chart

Dividend Payments by Quarter for Advaxis (NASDAQ:ADXS)

Last Updated on 2/22/2017 by MarketBeat.com Staff